Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXTERA SURGICAL INCDXTR · Entity 174504 | Director | November 22, 2016 | January 27, 2017 |
| STRATA Skin Sciences, Inc.SSKN · Entity 72980 | Director | October 09, 2020 | October 13, 2020 |
| Streamex Corp.BSGM · Entity 1816 | Director | December 28, 2021 | April 25, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXTERA SURGICAL INC
Report date November 22, 2016 · Filed January 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2023-11-22 | Direct | 15,000 |
Reported balance
After 2016-11-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-22 · Grant · Acquired 15,000 · Balance 15,000 F1: The options were granted under the Dextera Surgical 2016 Equity Incentive Plan and vest 1/12 per month starting 11/22/2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted under the Dextera Surgical 2016 Equity Incentive Plan and vest 1/12 per month starting 11/22/2016.
STRATA Skin Sciences, Inc.
Report date October 09, 2020 · Filed October 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SSKN Common StockSEC Table I · non-derivative | Direct | 66,136 |
Reported balance
After 2020-10-09 transaction · row 1
1 source rowRow 1 · 2020-10-09 · Exercise / conversion · Acquired 15,000 · Balance 66,136 |
| STRATA Skin Non-Qualified Stock Option (Option to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2027-12-01 | Direct | 0 |
Reported balance
After 2020-10-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-09 · Exercise / conversion · Disposed 15,000 · Balance 0 |
Streamex Corp.
Report date December 28, 2021 · Filed April 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 · Expires 2031-12-28 | Direct | 50,000 |
Reported balance
After 2021-12-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-28 · Grant · Acquired 50,000 · Balance 50,000 F1: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DERMA SCIENCES, INC.
Report date February 24, 2017 · Filed February 24, 2017
Section 16 reporting ended · disclosed 2017-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Ending reported balance
After 2017-02-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-02-24 · Disposition to issuer · Disposed 37,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2017, by and among the Issuer, Integra Derma, Inc. and Integra LifeSciences Holdings Corporation (the "Merger Agreement"), as of the Effective Time (as defined in the Merger Agreement), the shares of the Issuer's common stock were converted into the right to receive $7.00 per share to the reporting person in cash. Row 2 · 2017-02-24 · Disposition to issuer · Acquired 25,000 · Balance 25,000 F2: Represents shares of the Issuer's common stock received upon the vesting of 25,000 restricted stock units, as described herein. F4: The restricted stock units were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-02-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-24 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Upon the Effective Time, and in connection with a tender offer pursuant to which Integra Derma, Inc. offered to purchase all of the Issuer's common stock for $7.00 per share, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings. F4: The restricted stock units were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2017, by and among the Issuer, Integra Derma, Inc. and Integra LifeSciences Holdings Corporation (the "Merger Agreement"), as of the Effective Time (as defined in the Merger Agreement), the shares of the Issuer's common stock were converted into the right to receive $7.00 per share to the reporting person in cash.
F2: Represents shares of the Issuer's common stock received upon the vesting of 25,000 restricted stock units, as described herein.
F3: Upon the Effective Time, and in connection with a tender offer pursuant to which Integra Derma, Inc. offered to purchase all of the Issuer's common stock for $7.00 per share, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings.
F4: The restricted stock units were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 28, 2021 Filed Apr 25, 2022 17:18 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001185185-22-000495 · ownership.xml · derivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 09:52 UTC | Streamex Corp. BSGM · Entity 1816 | Exercise / conversionRestricted Stock Units ("RSUs") · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-21-000847 · ownership.xml · derivative · entry 2 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents the right to receive, at settlement, one (1) share of common stock. F2 · derivative.exercise_date: On June 21, 2019, the reporting person was granted 50,000 RSUs, with 50% to vest on June 21, 2020 and the remaining 50% to vest on June 21, 2021, subject to reporting person's continued service through each vest date. F2 · derivative.expiration_date: On June 21, 2019, the reporting person was granted 50,000 RSUs, with 50% to vest on June 21, 2020 and the remaining 50% to vest on June 21, 2021, subject to reporting person's continued service through each vest date. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 09:52 UTC | Streamex Corp. BSGM · Entity 1816 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001185185-21-000847 · ownership.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents the right to receive, at settlement, one (1) share of common stock. Read SEC document |
| May 25, 2021 Filed May 26, 2021 09:31 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 1,500 | $3.31 | $4,965.00 |
DisclosureSEC source: 0001185185-21-000724 · ownership.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 12:13 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | Exercise / conversionSTRATA Skin Non-Qualified Stock Option (Option to Buy) · Derivative | 15,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001051514-20-000048 · form4.xml · derivative · entry 2 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: SSKN Common Stock · 15,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 12:13 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | Exercise / conversionSSKN Common Stock | 15,000 | $1.29 | $19,350.00 |
DisclosureSEC source: 0001051514-20-000048 · form4.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 17:01 UTC | Streamex Corp. BSGM · Entity 1816 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $4.66 | Not disclosed |
DisclosureSEC source: 0001185185-20-001192 · ownership.xml · derivative · entry 2 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2030-04-14 F1 · price: The option was canceled by mutual agreement of the reporting person and BioSig Technologies, Inc. (the "Company"). The reporting person received 50,000 fully vested shares of restricted common stock of the Company, par value $0.001 per share, as consideration for the cancellation. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 17:01 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-20-001192 · ownership.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,500 Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 17:02 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-20-000953 · ownership.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,500 Read SEC document |
| June 21, 2020 Filed Jun 23, 2020 17:30 UTC | Streamex Corp. BSGM · Entity 1816 | Exercise / conversionRestricted Stock Units ("RSUs") · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-20-000888 · ownership.xml · derivative · entry 2 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents the right to receive, at settlement, one (1) share of common stock. F2 · derivative.exercise_date: On June 21, 2019, the reporting person was granted 50,000 RSUs, with 50% to vest on June 21, 2020 and the remaining 50% to vest on June 21, 2021, subject to reporting person's continued service through each vest date. F2 · derivative.expiration_date: On June 21, 2019, the reporting person was granted 50,000 RSUs, with 50% to vest on June 21, 2020 and the remaining 50% to vest on June 21, 2021, subject to reporting person's continued service through each vest date. Read SEC document |
| June 21, 2020 Filed Jun 23, 2020 17:30 UTC | Streamex Corp. BSGM · Entity 1816 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001185185-20-000888 · ownership.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents the right to receive, at settlement, one (1) share of common stock. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 11:42 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0001185185-20-000472 · ownership.xml · derivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-04-14 F1 · derivative.exercise_date: The option vested in full on April 14, 2020. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 16:38 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 14,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001051514-19-000131 · form4.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,136 F1 · security: Represents Restricted Stock Units issued to the recipient, in lieu of a portion of his Board compensation, on November 22, 2019 at the closing price of $2.46. The Restricted Stock Units will vest 100%, in equal quarterly installments, over a 12 month period. F2 · balance_after: Includes 16,908 fully vested Restricted Stock Units granted on June 8, 2018 and previously reported on Table II. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 17:18 UTC | Streamex Corp. BSGM · Entity 1816 | PurchaseCommon Stock, $0.001 par value per share | 1,000 | $6.46 | $6,460.00 |
DisclosureSEC source: 0001185185-19-001637 · ownership.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 13:03 UTC | Streamex Corp. BSGM · Entity 1816 | PurchaseCommon Stock, $0.001 par value per share | 2,500 | $6.99 | $17,475.00 |
DisclosureSEC source: 0001185185-19-001540 · ownership.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · price: Represents the weighted average price of shares purchased in multiple transactions at prices ranging from $6.91 to $7.03, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 15:05 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 29,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001185185-19-001476 · ownership.xml · derivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2029-10-30 F1 · derivative.exercise_date: The option vested on October 30, 2019. Read SEC document |
| June 21, 2019 Filed Jun 25, 2019 12:47 UTC | Streamex Corp. BSGM · Entity 1816 | GrantRestricted Stock Units ("RSUs") · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001185185-19-000915 · ownership.xml · derivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of common stock. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of common stock. F2 · derivative.exercise_date: This RSU award was granted on June 21, 2019. 50% of this RSU award shall vest on June 21, 2020, and the remaining 50% shall vest on June 21, 2021, subject to continued service through each vest date. F2 · derivative.expiration_date: This RSU award was granted on June 21, 2019. 50% of this RSU award shall vest on June 21, 2020, and the remaining 50% shall vest on June 21, 2021, subject to continued service through each vest date. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 18:08 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSTRATA Restricted Stock Units · Derivative | 16,908 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001140361-18-028128 · doc1.xml · derivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,908 Underlying: Common Stock · 16,908 shares Expires 2028-06-08 F1 · derivative.exercise_date: Restricted Stock Options will vest 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 10:20 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 5,600 | $1.99 | $11,144.00 |
DisclosureSEC source: 0001140361-18-027514 · doc1.xml · nonDerivative · entry 5 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 10:20 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 1,600 | $1.98 | $3,168.00 |
DisclosureSEC source: 0001140361-18-027514 · doc1.xml · nonDerivative · entry 4 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,400 Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 10:20 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 3,400 | $1.98 | $6,732.00 |
DisclosureSEC source: 0001140361-18-027514 · doc1.xml · nonDerivative · entry 3 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 10:20 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 2,400 | $1.97 | $4,728.00 |
DisclosureSEC source: 0001140361-18-027514 · doc1.xml · nonDerivative · entry 2 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,400 Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 10:20 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 7,000 | $2.05 | $14,350.00 |
DisclosureSEC source: 0001140361-18-027514 · doc1.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 13:56 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSTRATA Skin Non-Qualified Stock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001140361-17-044764 · doc1.xml · derivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-12-01 Read SEC document |
| February 24, 2017 Filed Feb 24, 2017 17:38 UTC | DERMA SCIENCES, INC. DSCI · Entity 178548 | Disposition to issuerRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-011044 · v460296_form4.xml · derivative · entry 3 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_price: Upon the Effective Time, and in connection with a tender offer pursuant to which Integra Derma, Inc. offered to purchase all of the Issuer's common stock for $7.00 per share, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings. F4 · price: The restricted stock units were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration. F3 · derivative.exercise_date: Upon the Effective Time, and in connection with a tender offer pursuant to which Integra Derma, Inc. offered to purchase all of the Issuer's common stock for $7.00 per share, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings. F3 · derivative.expiration_date: Upon the Effective Time, and in connection with a tender offer pursuant to which Integra Derma, Inc. offered to purchase all of the Issuer's common stock for $7.00 per share, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings. Read SEC document |
| February 24, 2017 Filed Feb 24, 2017 17:38 UTC | DERMA SCIENCES, INC. DSCI · Entity 178548 | Disposition to issuerCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-011044 · v460296_form4.xml · nonDerivative · entry 2 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F2 · shares: Represents shares of the Issuer's common stock received upon the vesting of 25,000 restricted stock units, as described herein. F4 · price: The restricted stock units were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration. Read SEC document |
| February 24, 2017 Filed Feb 24, 2017 17:38 UTC | DERMA SCIENCES, INC. DSCI · Entity 178548 | Disposition to issuerCommon Stock | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-011044 · v460296_form4.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2017, by and among the Issuer, Integra Derma, Inc. and Integra LifeSciences Holdings Corporation (the "Merger Agreement"), as of the Effective Time (as defined in the Merger Agreement), the shares of the Issuer's common stock were converted into the right to receive $7.00 per share to the reporting person in cash. Read SEC document |
| December 06, 2016 Filed Dec 7, 2016 12:42 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSTRATA Skin Non-Qualified Stock Options · Derivative | 75,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001140361-16-088958 · doc1.xml · derivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2026-12-06 Read SEC document |
| November 22, 2016 Filed Jan 27, 2017 18:55 UTC | DEXTERA SURGICAL INC DXTR · Entity 174504 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $1.36 Strike: $1.36 | $20,400.00 |
DisclosureSEC source: 0001437749-17-001272 · rdgdoc.xml · derivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2023-11-22 F1 · derivative.exercise_date: The options were granted under the Dextera Surgical 2016 Equity Incentive Plan and vest 1/12 per month starting 11/22/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.